Nestlé has divested its peanut allergy treatment business, Palforzia, to biopharmaceutical company Stallergenes Greer.
Headquartered in Switzerland, Stallergenes Greer specialises in the diagnosis and treatment of respiratory allergies through immunotherapy.
The deal follows Nestlé’s announcement last year, stating its intention to undertake a strategic review of Palforzia. The food giant said it will “receive milestone payments and ongoing royalties” from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said: “We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world. At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers.”
According to the company, a customary transition period will be implemented to ensure business continuity and to provide patients with uninterrupted access to the treatment.
Terms of the transaction were not disclosed.
By Rafaela Sousa
Source: foodbev.com
During Investor’s Day, Mick Beekhuizen, EVP and president of Meals & Beverages, said that while soup remains an important part of the company’s portfolio, it accounts for a smaller portion than in the past. As a result, the enterprise is petitioning the board to rename the business to Campbell’s Company, subject to approval in November.
The two beverage giants agreed on the deal in July 2024, after Britvic previously rejected an offer of £3bn (approx. $3.95bn) from the Danish brewer in June. Britvic revealed that Carlsberg’s revised offer had the approval of its board and was expected to close in the fourth quarter of 2024, subject to regulatory approvals.
LinkedIn Twitter Xing EmailGeneral Mills has announced definitive agreements to sell its North American yogurt operations to Lactalis and Sodiaal, two French dairy firms, in a move valued at approximately […]
